Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AT-1501-K207: BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

NCT05983770 is registered in ClinicalTrials.gov with Eledon Pharmaceuticals as lead sponsor.

NCT NCT05983770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05983770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AT-1501-K207: BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Lead sponsor
Eledon Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
August 30, 2023
Completion date
September 25, 2025
Enrollment
127 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant rejection